Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer

被引:71
作者
Zhang, Huijun [1 ,2 ]
Dutta, Pranabananda [1 ]
Liu, Jinguo [2 ]
Sabri, Nafiseh [1 ]
Song, Yuanlin [2 ]
Li, Willis X. [1 ]
Li, Jinghong [1 ]
机构
[1] Univ Calif San Diego, Dept Med, Div Pulm & Crit Care Med, La Jolla, CA 92093 USA
[2] Fudan Univ, Dept Pulm Med, Zhongshan Hosp, Shanghai, Peoples R China
关键词
CTLA4; EGFR; NSCLC; PD-1; PD-L1; IMMUNE ESCAPE; UP-REGULATION; ACTIVATION; IPILIMUMAB; BLOCKADE; IMMUNOTHERAPY; MULTICENTER; CONTRIBUTES; NIVOLUMAB; EFFECTOR;
D O I
10.1111/jcmm.13956
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Cytotoxic T lymphocyte antigen 4 (CTLA4) and programmed cell death protein 1 (PD-1) are immune checkpoint proteins expressed in T cells. Although CTLA4 expression was found in multiple tumours including non-small cell lung cancer (NSCLC) tissues and cells, its function in tumour cells is unknown. Recently, PD-1 was found to be expressed in melanoma cells and to promote tumorigenesis. We found that CTLA4 was expressed in a subset of NSCLC cell lines and in a subgroup of cancer cells within the lung cancer tissues. We further found that in NSCLC cells, anti-CTLA4 antibody can induce PD-L1 expression, which is mediated by CTLA4 and the EGFR pathway involving phosphorylation of MEK and ERK. In CTLA4 knockout cells, EGFR knockout cells or in the presence of an EGFR tyrosine kinase inhibitor, anti-CTLA4 antibody was not able to induce PD-L1 expression in NSCLC cells. Moreover, anti-CTLA4 antibody promoted NSCLC cell proliferation in vitro and tumour growth in vivo in the absence of adaptive immunity. These results suggest that tumour cell-intrinsic CTLA4 can regulate PD-L1 expression and cell proliferation, and that anti-CTLA4 antibody, by binding to the tumour cell-intrinsic CTLA4, may result in the activation of the EGFR pathway in cancer cells.
引用
收藏
页码:535 / 542
页数:8
相关论文
共 28 条
[1]   Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].
Akbay, Esra A. ;
Koyama, Shohei ;
Carretero, Julian ;
Altabef, Abigail ;
Tchaicha, Jeremy H. ;
Christensen, Camilla L. ;
Mikse, Oliver R. ;
Cherniack, Andrew D. ;
Beauchamp, Ellen M. ;
Pugh, Trevor J. ;
Wilkerson, Matthew D. ;
Fecci, Peter E. ;
Butaney, Mohit ;
Reibel, Jacob B. ;
Soucheray, Margaret ;
Cohoon, Travis J. ;
Janne, Pasi A. ;
Meyerson, Matthew ;
Hayes, D. Neil ;
Shapiro, Geoffrey I. ;
Shimamura, Takeshi ;
Sholl, Lynette M. ;
Rodig, Scott J. ;
Freeman, Gordon J. ;
Hammerman, Peter S. ;
Dranoff, Glenn ;
Wong, Kwok-Kin .
CANCER DISCOVERY, 2013, 3 (12) :1355-1363
[2]   CTLA-4 Expression and Polymorphisms in Lung Tissue of Patients with Diagnosed Non-Small-Cell Lung Cancer [J].
Antczak, Adam ;
Pastuszak-Lewandoska, Dorota ;
Gorski, Pawel ;
Domanska, Daria ;
Migdalska-Sek, Monika ;
Czarnecka, Karolina ;
Nawrot, Ewa ;
Kordiak, Jacek ;
Brzezianska, Ewa .
BIOMED RESEARCH INTERNATIONAL, 2013, 2013
[3]   Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].
Azuma, K. ;
Ota, K. ;
Kawahara, A. ;
Hattori, S. ;
Iwama, E. ;
Harada, T. ;
Matsumoto, K. ;
Takayama, K. ;
Takamori, S. ;
Kage, M. ;
Hoshino, T. ;
Nakanishi, Y. ;
Okamoto, I. .
ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940
[4]   Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future [J].
Chen, Lieping ;
Han, Xue .
JOURNAL OF CLINICAL INVESTIGATION, 2015, 125 (09) :3384-3391
[5]   Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation [J].
Chen, Nan ;
Fang, Wenfeng ;
Zhan, Jianhua ;
Hong, Shaodong ;
Tang, Yanna ;
Kang, Shiyang ;
Zhang, Yaxiong ;
He, Xiaobo ;
Zhou, Ting ;
Qin, Tao ;
Huang, Yan ;
Yi, Xianping ;
Zhang, Li .
JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (06) :910-923
[6]   CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction [J].
Contardi, E ;
Palmisano, GL ;
Tazzari, PL ;
Martelli, AM ;
Falà, F ;
Fabbi, M ;
Kato, T ;
Lucarelli, E ;
Donati, D ;
Polito, L ;
Bolognesi, A ;
Ricci, F ;
Salvi, S ;
Gargaglione, V ;
Mantero, S ;
Alberghini, M ;
Ferrara, GB ;
Pistillo, MP .
INTERNATIONAL JOURNAL OF CANCER, 2005, 117 (04) :538-550
[7]   PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients [J].
D'Incecco, A. ;
Andreozzi, M. ;
Ludovini, V. ;
Rossi, E. ;
Capodanno, A. ;
Landi, L. ;
Tibaldi, C. ;
Minuti, G. ;
Salvini, J. ;
Coppi, E. ;
Chella, A. ;
Fontanini, G. ;
Filice, M. E. ;
Tornillo, L. ;
Incensati, R. M. ;
Sani, S. ;
Crino, L. ;
Terracciano, L. ;
Cappuzzo, F. .
BRITISH JOURNAL OF CANCER, 2015, 112 (01) :95-102
[8]   Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4 [J].
Dias, J. D. ;
Hemminki, O. ;
Diaconu, I. ;
Hirvinen, M. ;
Bonetti, A. ;
Guse, K. ;
Escutenaire, S. ;
Kanerva, A. ;
Pesonen, S. ;
Loskog, A. ;
Cerullo, V. ;
Hemminki, A. .
GENE THERAPY, 2012, 19 (10) :988-998
[9]  
Finn PW, 1997, J IMMUNOL, V158, P4074
[10]   Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer [J].
Garon, Edward B. ;
Rizvi, Naiyer A. ;
Hui, Rina ;
Leighl, Natasha ;
Balmanoukian, Ani S. ;
Eder, Joseph Paul ;
Patnaik, Amita ;
Aggarwal, Charu ;
Gubens, Matthew ;
Horn, Leora ;
Carcereny, Enric ;
Ahn, Myung-Ju ;
Felip, Enriqueta ;
Lee, Jong-Seok ;
Hellmann, Matthew D. ;
Hamid, Omid ;
Goldman, Jonathan W. ;
Soria, Jean-Charles ;
Dolled-Filhart, Marisa ;
Rutledge, Ruth Z. ;
Zhang, Jin ;
Lunceford, Jared K. ;
Rangwala, Reshma ;
Lubiniecki, Gregory M. ;
Roach, Charlotte ;
Emancipator, Kenneth ;
Gandhi, Leena .
NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (21) :2018-2028